Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414765 · ClinicalTrials.gov registry record · Phase 4
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT00414765 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT00414765, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
Interventions
- DRUG Aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-09-03 |
| Est. Completion | 2010-03-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414765
The ClinicalTrials.gov registry entry for NCT00414765 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aldesleukin is the first listed.
NCT00414765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414765 about?
NCT00414765 is a clinical study titled "Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma". This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.
What is the current status of trial NCT00414765?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2008-09-03. Estimated completion is 2010-03-28.
What interventions are being tested in trial NCT00414765?
The interventions under investigation include: Aldesleukin (DRUG).
Who is sponsoring clinical trial NCT00414765?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.